Today: 30 April 2026
Browse Category

NASDAQ:ISRG 13 December 2025 - 15 January 2026

Why Intuitive Surgical stock (ISRG) is back in focus after Bernstein lifts its target

Why Intuitive Surgical stock (ISRG) is back in focus after Bernstein lifts its target

Intuitive Surgical shares closed Friday at $586.24, up 0.2%, after Bernstein and Goldman Sachs raised their price targets to $740 and $714, respectively. The company will present at the J.P. Morgan Healthcare Conference on Jan. 14 and report Q4 earnings Jan. 22. Investors are focused on da Vinci 5 adoption and procedure growth. The stock’s 52-week range is $425 to $616.
10 January 2026
·
Intuitive Surgical stock jumps as investors eye JPM healthcare conference and Jan. 22 earnings

Intuitive Surgical stock jumps as investors eye JPM healthcare conference and Jan. 22 earnings

Intuitive Surgical shares closed up 4.6% at $592.85 Tuesday and gained another 0.4% after hours. Evercore ISI raised its price target to $580, citing strong procedure and capital spending trends but kept an “In Line” rating. Trading volume reached 2.63 million shares. The company will present at the J.P. Morgan Healthcare Conference on Jan. 14 and report earnings Jan. 22.
7 January 2026
··
Intuitive Surgical stock falls today: what’s driving ISRG and what investors watch next

Intuitive Surgical stock falls today: what’s driving ISRG and what investors watch next

Intuitive Surgical shares fell 1% to $560.61 in Friday’s afternoon trading, underperforming a mixed U.S. market on the first session of 2026. The move followed a management shift, with Chief Digital Officer Brian E. Miller taking a new role focused on digital and AI strategy. Medical-device stocks lagged, while broader healthcare edged higher. Investors are watching upcoming jobs and inflation data, plus the J.P. Morgan Healthcare Conference.
2 January 2026
·
Intuitive Surgical (ISRG) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Intuitive Surgical (ISRG) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Intuitive Surgical shares traded near $577.15 ahead of the Dec. 26 session after the FDA cleared expanded uses for its da Vinci SP system on Dec. 10, including hernia and gallbladder procedures. The FDA recall database lists two open Class II recalls for da Vinci 5 components, posted Dec. 19, affecting 144 units due to an ergonomic connector issue that can cause delays or require system restarts.
26 December 2025
·
Intuitive Surgical (ISRG) News, Analyst Forecasts and 2026 Outlook: FDA Expansion for da Vinci SP, Wall Street Targets, and What’s Next (Dec. 25, 2025)

Intuitive Surgical (ISRG) News, Analyst Forecasts and 2026 Outlook: FDA Expansion for da Vinci SP, Wall Street Targets, and What’s Next (Dec. 25, 2025)

The FDA cleared expanded indications for Intuitive Surgical’s da Vinci SP robotic system on December 10, 2025, adding inguinal hernia repair, cholecystectomy, and appendectomy. ISRG shares closed at $578 on December 24, with Q4 earnings expected in late January. Brian E. Miller will become Head of Digital and AI Strategy on January 1, 2026.
25 December 2025
·
Intuitive Surgical (ISRG) Stock After Hours on Dec. 23, 2025: What’s Moving Shares and What to Watch Before the Dec. 24 Market Open

Intuitive Surgical (ISRG) Stock After Hours on Dec. 23, 2025: What’s Moving Shares and What to Watch Before the Dec. 24 Market Open

Intuitive Surgical shares closed Tuesday at $577.34, down 0.43%, and edged up 0.05% to $577.60 in after-hours trading. The S&P 500 finished near record highs as holiday trading volumes thinned. U.S. markets will close early at 1:00 p.m. ET on Wednesday, Dec. 24. Initial jobless claims data is due before the open.
24 December 2025
··
Intuitive Surgical Stock (ISRG) Week Ahead: FDA da Vinci 5 Recall Posting, da Vinci SP Expansion, and Fresh Wall Street Targets Into the Christmas Trading Week

Intuitive Surgical Stock (ISRG) Week Ahead: FDA da Vinci 5 Recall Posting, da Vinci SP Expansion, and Fresh Wall Street Targets Into the Christmas Trading Week

The FDA posted a Class 2 recall for Intuitive Surgical’s da Vinci 5 console component on December 19. Days earlier, the FDA cleared da Vinci SP for use in three general surgery procedures. ISRG stock closed at $572.47 Friday, up 1.88% with trading volume nearly double its 50-day average. Shares sit about 7% below their 52-week high.
22 December 2025
··
Intuitive Surgical (ISRG) Stock: Latest News, Analyst Forecasts, and 2026 Outlook (Updated Dec. 20, 2025)

Intuitive Surgical (ISRG) Stock: Latest News, Analyst Forecasts, and 2026 Outlook (Updated Dec. 20, 2025)

Intuitive Surgical shares closed at $572.47 on Friday, Dec. 19, up 1.88% after the FDA cleared its da Vinci SP system for three new procedures. The stock rebounded from mid-December lows and gained 1.75% over the month. Analysts raised price targets toward $650 heading into 2026. Investors are watching for further adoption of the single-port platform.
21 December 2025
·
Intuitive Surgical Stock (ISRG) News Today: Price Action, Analyst Forecasts, and What to Watch on December 16, 2025

Intuitive Surgical Stock (ISRG) News Today: Price Action, Analyst Forecasts, and What to Watch on December 16, 2025

Intuitive Surgical shares fell about 2% to $548–$549 in late morning trading Tuesday, following a 3.17% rebound Monday that ended a five-day losing streak. The company’s market cap stood near $194 billion. Technical analysts noted the stock’s Relative Strength Rating rose to 81. Recent SEC filings showed mixed institutional activity, with Orion Portfolio Solutions increasing its stake and Nilsine Partners reducing holdings.
16 December 2025
·
Intuitive Surgical (ISRG) Stock News Today: What’s Driving Shares, Latest Analyst Forecasts, and Key Catalysts for 2026 (Dec. 15, 2025)

Intuitive Surgical (ISRG) Stock News Today: What’s Driving Shares, Latest Analyst Forecasts, and Key Catalysts for 2026 (Dec. 15, 2025)

Intuitive Surgical shares rose about 3% to near $558 on Dec. 15, 2025, amid heavy institutional-filing headlines and options market activity. SevenBridge Financial Group boosted its ISRG stake by 68.6%, while Silicon Valley Capital Partners cut its position by 96.5%. Texas Permanent School Fund and Neville Rodie & Shaw also trimmed holdings. Corient Private Wealth increased its stake by 68.8%.
15 December 2025
·
Intuitive Surgical Stock News: ISRG Drops ~4% This Week Despite FDA Clearance, Citi Downgrade, and New Price Targets (Updated Dec. 12, 2025)

Intuitive Surgical Stock News: ISRG Drops ~4% This Week Despite FDA Clearance, Citi Downgrade, and New Price Targets (Updated Dec. 12, 2025)

Intuitive Surgical shares fell 4.3% this week, closing at $542.32 Friday after five straight declines. The drop followed FDA clearance expanding da Vinci SP’s U.S. indications, a Citigroup downgrade, a Wells Fargo price-target hike, and insider selling disclosures. ISRG now trades about 12% below its 52-week high.
13 December 2025
·
Intuitive Surgical (ISRG) Stock After Hours on Dec. 12, 2025: Wells Fargo Raises Target, Insider Filing Surfaces—What to Know Ahead of the Next Market Open

Intuitive Surgical (ISRG) Stock After Hours on Dec. 12, 2025: Wells Fargo Raises Target, Insider Filing Surfaces—What to Know Ahead of the Next Market Open

Intuitive Surgical (ISRG) closed Friday, Dec. 12, 2025, at $542.32, down 0.92%, with after-hours trading flat near $542.00. Shares moved between $537.70 and $548.93 on volume of 2.08 million. Wells Fargo raised its price target to $654 and kept an Overweight rating. U.S. markets are closed Saturday; next regular session is Monday.
13 December 2025
·
Intuitive Surgical (ISRG) Stock After Hours Dec. 12, 2025: Citi Downgrade, Wells Fargo Price Target Raise, Insider Filing — What to Know Before the Next Market Open

Intuitive Surgical (ISRG) Stock After Hours Dec. 12, 2025: Citi Downgrade, Wells Fargo Price Target Raise, Insider Filing — What to Know Before the Next Market Open

Intuitive Surgical closed Friday at $542.32, down 0.92%, then traded nearly flat after hours. The stock moved amid a Citigroup downgrade to Neutral with a $635 target and a Wells Fargo target hike to $654. VP Mark Brosius filed to sell 5,276 shares under a 10b5-1 plan. Quantinno increased its stake, according to MarketBeat.
13 December 2025
·
1 2 3

Stock Market Today

  • Needham & Company Raises Alphabet (GOOGL) Price Target to $450, Citing Strong Upside
    April 30, 2026, 8:48 AM EDT. Needham & Company LLC upgraded Alphabet Inc. (NASDAQ: GOOGL) stock target from $400 to $450, reflecting a potential 28.6% gain. The firm reiterates a "buy" rating on the tech giant. Other analysts, including Robert W. Baird and Wedbush, also raised their price targets, indicating broad bullish sentiment. Alphabet's shares opened at $349.94 with a $4.23 trillion market cap. The company posted impressive earnings of $5.11 per share for Q1, beating estimates by $2.47. Revenue topped $109.9 billion, higher than expected. Alphabet maintains a solid return on equity of 35.01% and a net margin of nearly 33%. Insider John L. Hennessy's recent sale of shares was noted but does not appear to impact overall positive analyst outlooks.

Latest article

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

30 April 2026
Qualcomm shares rose 10.3% premarket Thursday after CEO Cristiano Amon said the smartphone market had bottomed and highlighted progress in data-center chips. Fiscal Q2 revenue fell 3% to $10.6 billion, with handset revenue down 13% but automotive up 38%. The Q3 forecast missed Wall Street estimates. Qualcomm expects chip sales to Chinese handset makers to recover after Q3.
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

30 April 2026
Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
Go toTop